Outpatient Microdose Induction with Transdermal Buprenorphine: A Case Series

Transdermal buprenorphine is FDA approved for chronic severe pain but has an increasing amount of data supporting its use to transition patients from full opioid agonists to sublingual buprenorphine via a microdose strategy. The literature has primarily focused on patients with a pain diagnosis or w...

Descripción completa

Detalles Bibliográficos
Autores principales: Menard, Shannon, Jhawar, Archana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9317019/
https://www.ncbi.nlm.nih.gov/pubmed/35885833
http://dx.doi.org/10.3390/healthcare10071307

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9317019/
https://www.ncbi.nlm.nih.gov/pubmed/35885833
http://dx.doi.org/10.3390/healthcare10071307

Ejemplares similares